Abstract:Heba Abdel-Halim, 1, *, † Malak Hajar 1, † , Luma Hasouneh 1, † , Suzanne MA Abdelmalek 2, † 1 Department of Medicinal Chemistry, Faculty of Pharmacy and Medical Sciences, University of Petra, Amman, Jordan; 2 Department of Pharmacology and Biomedical Sciences, Faculty of Pharmacy and Medical Sciences, University of Petra, Amman, Jordan †Dr Abdel-Halim passed away on July 14, 2022 *These authors contributed equally to this work Correspondence: Suzanne MA Abdelmalek, Department of Pharmacology and Biomedical Sciences, Faculty of Pharmacy and Medical Sciences, University of Petra, P.O. Box 961343, Amman, 11196, Jordan, Tel +962-6-5799555 Ext. (8310), Fax +962-65715570, Email Purpose: The development of effective treatments for coronavirus infectious disease 19 (COVID-19) caused by SARS-Coronavirus-2 was hindered by the little data available about this virus at the start of the pandemic. Drug repurposing provides a good strategy to explore approved drugs' possible SARS-CoV-2 antiviral activity. Moreover, drug synergism is essential in antiviral treatment due to improved efficacy and reduced toxicity. In this work, we studied the effect of approved and investigational drugs on one of SARS-CoV-2 essential proteins, the main protease (M pro ), in search of antiviral treatments and/or drug combinations. Methods: Different possible druggable sites of M pro were identified and screened against an in-house library of more than 4000 chemical compounds. Molecular dynamics simulations were carried out to explore conformational changes induced by different ligands' binding. Subsequently, the inhibitory effect of the identified compounds and the suggested drug combinations on the M pro were established using a 3CL protease (SARS-CoV-2) assay kit. Results: Three potential inhibitors in three different binding sites were identified; favipiravir, cefixime, and carvedilol. Molecular dynamics simulations predicted the synergistic effect of two drug combinations: favipiravir/cefixime, and favipiravir/carvedilol. The in vitro inhibitory effect of the predicted drug combinations was established on this enzyme. Conclusion: In this work, we could study one of the promising SARS-CoV-2 viral protein targets in searching for treatments for COVID-19. The inhibitory effect of several drugs on M pro was established in silico and in vitro assays. Molecular dynamics simulations showed promising results in predicting the synergistic effect of drug combinations. Keywords: molecular dynamics simulations, ligand docking, multiple binding sites, drug synergy, SARS-CoV-2 The outbreak of COVID-19 was declared a pandemic by the World Health Organization in March 2020. Almost 520 million cases and more than 6 million deaths were reported. Many drugs that have been used since the outbreak's start were proven futile in compacting the infection. Recently, a newly developed drug was approved for clinical use in severe or critical COVID-19 conditions. However, more drugs are still needed to reduce the impact of this pandemic. Due to the limited time and the urgent need for a treatment, we proposed an in silico approach to explore the effect of approved drugs on one of the important virus targets, the main protease (M pro ). In this work, we have established the inhibitory effect of three drugs and two drug combinations on this enzyme. COVID-19 is caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). 1 With more than 520 million people infected and around 6 million reported deaths, COVID-19 represents a serious menace to the world's public health and economies. 2 Many of the treatment approaches that have been employed since the beginning of the pandemic were proven ineffective in targeting the virus. 3–5 Therefore, there is an imminent need to identify drugs that can be effectively used to treat COVID-19. Coronaviruses are enveloped single-stranded positive-sense RNA viruses that belong to the family Coronaviridae . They are widely distributed in humans and other mammals. 6 The SARS-CoV has a large genome (comprised of ≈29,700 nucleotides) that encodes structural and non-structural proteins. 7 The virus replication and transcription occurs at cytoplasmic membranes and involves RNA synthesis mediated by the viral replicase gene products. The replicase gene of SARS-CoV-2 encodes two overlapping polyproteins–pp1a and pp1ab–that are required for viral replication and transcription. 8 Extensive proteolytic processing of these polypeptides takes place by the activity of the 33.8-kDa M<s -Abstract Truncated-

Spontaneous binding of potential COVID-19 drugs (Camostat and Nafamostat) to human serine protease TMPRSS2

Spontaneous Binding of Potential COVID-19 Drugs to Human Serine Protease TMPRSS2

Structure-based Virtual Screening, in Silico Docking, ADME Properties Prediction and Molecular Dynamics Studies for the Identification of Potential Inhibitors Against SARS-CoV-2 Mpro.

A Search for Medications to Treat COVID-19 Via in Silico Molecular Docking Models of the SARS-CoV-2 Spike Glycoprotein and 3CL Protease

Computational View Toward the Inhibition of SARS-CoV-2 Spike Glycoprotein and the 3CL Protease.

REVISITING THE SARS-COV-2 MAIN PROTEASE: A 2023 IN SILICO ODYSSEY IN SEARCH OF POTENTIAL INHIBITORS

Relaxed complex scheme and molecular dynamics simulation suggests small molecule inhibitor of human TMPRSS2 for combating COVID-19

Identification of potent inhibitors against transmembrane serine protease 2 for developing therapeutics against SARS-CoV-2

Repurposing of approved drugs and nutraceuticals to identify potential inhibitors of SARS-COV-2’s entry into human host cells: a structural analysis using induced-fit docking, MMGBSA and molecular dynamics simulation approach

Molecular Modeling Evaluation of the Binding Effect of Five Protease Inhibitors to COVID-19 Main Protease.

Fast Identification of Possible Drug Treatment of Coronavirus Disease-19 (COVID-19) through Computational Drug Repurposing Study

Semi-Mechanistic Pharmacokinetic-Pharmacodynamic Model of Camostat Mesylate-Predicted Efficacy against SARS-CoV-2 in COVID-19

Computational Discovery of SARS-CoV-2 Main Protease Inhibitors Via a Virtual Screening, Molecular Docking, Molecular Dynamics and MM/PBSA Calculations-Driven Approach

Highlights in TMPRSS2 inhibition mechanism with guanidine derivatives approved drugs for COVID-19 treatment

Profiling SARS-CoV-2 Main Protease (MPRO) Binding to Repurposed Drugs Using Molecular Dynamics Simulations in Classical and Neural Network-Trained Force Fields

Identification of possible SARS-CoV-2 main protease inhibitors: in silico molecular docking and dynamic simulation studies

Identification of Drug Combination Therapies for SARS-CoV-2: A Molecular Dynamics Simulations Approach

Binding Kinetics Study of SARS-CoV-2 Main Protease and Potential Inhibitors Via Molecular Dynamics Simulations.

Mechanism of N-0385 blocking SARS-CoV-2 to treat COVID-19 based on molecular docking and molecular dynamics

An in-silico evaluation of COVID-19 main protease with clinically approved drugs

Evaluation of the Binding Affinity of Anti-Viral Drugs against Main Protease of SARS-CoV-2 Through a Molecular Docking Study